Board of Directors

Bernd Brust, Chairman of the Board and CEO of Cole-Parmer

Bernd Brust, Chairman and CEO

Bernd Brust serves as Chairman of the Board and CEO of Cole-Parmer Instrument Company. Before joining Cole-Parmer, Mr. Brust served as president and CEO of Qualicaps, a leading provider of capsule manufacturing and processing equipment for pharmaceutical companies, which sold to Mitsubishi Chemical Holdings in 2013.

Prior to his role with Qualicaps, Mr. Brust was Chief Commercial Operations Officer at Life Technologies Corporation and responsible for a $3.5 billion global business. Mr. Brust held prior leadership roles with Invitrogen Corporation (a predecessor to Life Technologies) and with GE Medical Systems.

 

Constantine Mihas, Board of Directors

Constantine (Dean) Mihas

Dean joined GTCR in 2001 and is currently a Managing Director of the firm. Prior to joining GTCR, Dean was CEO and co-founder of Delray Farms, LLC, a specialty food retailer. Prior to Delray Farms, Dean was with McKinsey & Company. Dean holds an MBA with distinction from the Harvard Business School and a BS with high distinction in finance and economics from the University of Illinois, Chicago.

Dean is head of the Healthcare group at GTCR and has been instrumental in building the firm’s expertise in life sciences and medical devices.  In addition to serving as a Director of Cole-Parmer, he is currently a Director of Albany Molecular, Cebatech, Cedar Gate Technologies, Corza Health, Maravai LifeSciences, Riverchase Dermatology, Regatta Medical, Rx30, Sotera, TerSera and XIFIN. Dean was previously a Director of past GTCR investments, including Actient Pharmaceuticals, ATI Physical Therapy, Convergex, Cord Blood Registry, Crealta Pharmaceuticals, Curo Health Services, Dash, Devicor Medical Products, GreatCall, Ovation Pharmaceuticals, Managed Healthcare Associates and Polypore.

Dean’s interest in the community is evident by his strong support of WBEZ Chicago Public Media, a non-commercial, public radio station financed primarily by listener contributions, where he serves as a board member and chair of the finance committee.

 

Sean Cunningham, Board of Directors

Sean Cunningham

Sean joined GTCR in 2001 and is currently a Managing Director of the firm. He was previously a Consultant with The Boston Consulting Group. Sean holds an MBA from the Wharton School at the University of Pennsylvania as well as AB and BE degrees in engineering sciences from Dartmouth College.

In addition to serving as Director of Cole-Parmer, Sean currently is a Director of Albany Molecular Research, Ceba-Tech, Cedar Gate Technologies, Corza Health, Maravai LifeSciences, Regatta, Riverchase Dermatology, Sotera and Transaction Data Systems. He was instrumental in GTCR’s past investments in Cord Blood Registry, Devicor Medical Products, Graceway Pharmaceuticals and Ovation Pharmaceuticals.

 

Ben Daverman, Board of Directors

Ben Daverman

Ben joined GTCR in 2008 and is currently a Managing Director of the firm. Prior to joining GTCR, he worked as a Venture Capitalist at Alta Partners, as well as an Investment Banking Associate at JMP Securities and an Analyst in the Mergers & Acquisitions group at J.P. Morgan (formerly Hambrecht & Quist). He holds an MBA from the Wharton School at the University of Pennsylvania and a BA in history magna cum laude from Colgate University. Ben also holds a master’s degree in biotechnology from the School of Applied Sciences & Engineering at the University of Pennsylvania.

In addition to serving as a Director of Cole-Parmer, he is currently a Director of Albany Molecular Research, Corza Health, Maravai LifeSciences, TerSera and XIFIN.

Ben was previously a Director of past GTCR investments such as Actient Pharmaceuticals and Cord Blood Registry, Crealta Pharmaceuticals, Devicor Medical Products, GeneraMedix and Sterigenics. In addition, Ben was involved in transactions with past GTCR investments ATI Physical Therapy and Graceway Pharmaceuticals.

Ben is active in the community and serves on the executive board of Spark Program, a national non-profit that provides transformative apprenticeships for at-risk middle-school students.

 

Jim Rauh, Principal, Golden Gate Capital

Jim Rauh

Jim Rauh joined the Board of Cole-Parmer in March 2017. Mr. Rauh focuses primarily on Golden Gate Capital’s equity investments in the industrials sector. Prior to joining Golden Gate Capital, Mr. Rauh was with JLL Partners, a New York-based private equity firm. Previously, he was an investment banker at J.P. Morgan. Mr. Rauh has a BA in Economics and Mathematical Methods in the Social Sciences from Northwestern University (summa cum laude, Phi Beta Kappa).

 

Robert Kirby, Operating Executive, Golden Gate Capital

Robert Kirby

Robert Kirby joined the Board of Cole-Parmer in March 2017. Mr. Kirby is an Operating Partner with Golden Gate Capital and currently serves as CEO of Atrium Windows, a Golden Gate Capital portfolio company. Mr. Kirby was previously CEO of Vi-Jon, a leading private label manufacturer in the personal care market. Prior to this Mr. Kirby was CEO of Accellent, a leading contract manufacturer in the medical device market. Earlier in Mr. Kirby’s career, he was a GM and led R&D, Global Manufacturing & Supply Chain at large cap companies, including Johnson & Johnson, Kimberly Clark and Fort James. Mr. Kirby has broad based experience in Consumer Personal Care, OTC and Medical Devices. During his 30 year career he has led large scale and complex integrations of acquisitions, implemented lean processes and driven rapid, positive change.

 

Greg Lucier, Board of Directors

Greg Lucier

Greg Lucier serves as the CEO of Corza Health and founded Corza Health in partnership with GTCR to combine his 30+ years of life sciences leadership with GTCR’s unrivaled track record of creating unique, value-generating private equity opportunities.

Greg most recently served as CEO at NuVasive, a world leader in minimally invasive spine surgery technology. Prior to that, he was CEO at Life Technologies—formerly Invitrogen—which he grew into a global life sciences powerhouse that was acquired by Thermo Fisher Scientific. He spent the first part of his career with the General Electric Company in a variety of executive roles. 

In addition to serving as a Director of Cole-Parmer, Lucier remains the Chairman of Nuvasive, and serves on several public and private company boards, including Catalent, a leader in advanced pharmaceutical manufacturing services, Dentsply Sirona, a global provider of professional dental products and technologies, and Epic Sciences, a venture-backed company revolutionizing the use of cellular imaging to change cancer therapy.

 

Dennis Pope, Board of Directors

Dennis Pope

Dennis Pope joined the Board of Cole-Parmer in September 2014. Mr. Pope brings a truly unique background to the Board as he has served in leadership capacities for both Cole-Parmer and Environmental Express. Mr. Pope served as Chief Executive Officer at Environmental Express from 2006 to 2013. Prior to his role at EE, he served as President at Kendro Laboratory Products, Division of SPX Corporation from 2000 to 2005 and he also served at Executive VP and COO at Cole-Parmer from 1996 to 2000.